在黑色素瘤中,YAP1通过重编程染色质和调节免疫逃避程序来驱动攻击性和耐治疗状态
bioRxiv : the preprint server for biology
|September 26, 2025
概括
通过改变色素,YAP1激活驱动黑色素瘤的治疗耐药性. 用特定的抑制剂向TEAD可以克服这种耐药性并增强抗瘤免疫力,为患者提供新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- BRAF/MEK 抑制剂显示有前途,但在50%的黑色素瘤患者中会出现抗药性.
- 了解耐药机制对于改善黑色素瘤治疗结果至关重要.
研究的目的:
- 研究YAP1在转移性黑色素瘤中BRAF/MEK抑制剂耐药性的作用.
- 确定针对YAP1介导抗性的治疗策略.
主要方法:
- 与转移性黑色素瘤的存活率相关联的YAP1激活.
- 研究YAP1与BRD4和TEAD在染色质重塑中的相互作用.
- 分析YAP1目标基因表达的临床活检.
- 在临床前模型中评估BRD4/TEAD的药理抑制.
- 在体内评估TEAD抑制剂与免疫检查点阻塞的协同作用.
主要成果:
- 在转移性黑色素瘤中,强大的YAP1激活与生存率差相关.
- YAP1,与BRD4和TEAD一起,重塑染色质以维持瘤信号和耐药性.
- 在耐性黑色素瘤活检中,YAP1目标基因表达升高.
- 抑制BRD4或TEAD可以降低YAP1转录,并重新激活抗瘤免疫力.
- TEAD抑制剂与免疫检查点阻塞协同作用,在黑色素瘤小鼠模型中增加CD8+T细胞透和存活率.
结论:
- 通过染色质重塑,YAP1激活是黑色素瘤中BRAF/MEK抑制剂耐药性的关键驱动因素.
- 针对性TEAD特别提出了一个有前途的双重战略,以克服耐药性和增强抗瘤免疫力.
- TEAD抑制剂为BRAF/MEK抑制剂耐药黑色素瘤提供了一种新的治疗途径.
更多相关视频
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
11.5K
10:03Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes
Published on: November 11, 2016
10.2K
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
The Intrinsic Apoptotic Pathway
8.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.3K
Adaptive Mechanisms in Cancer Cells
7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Induced Pluripotent Stem Cells
5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.4K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
